ArticleClinical and translational allergy2025
Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?
Article in Clinical and translational allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Can Synthetic Data Allow for Smaller Sample Sizes in Chronic Urticaria Research?Clinical and translational allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobust data are essential for clinical and epidemiological research, yet in chronic spontaneous urticaria (CSU), certain patient groups, such as the elderly or comorbid patients, are often underrepresented. In clinical trials, strict inclusion and exclusion criteria frequently limit recruitment, making it difficult to achieve sufficient statistical power. Similarly, real-world observational studies may lack sufficient sample sizes for robust analysis. To address these limitations, we generated synthetic patient data that reflect these groups' clinical characteristics and variability. This approach enables more comprehensive analyses, facilitates hypothesis testing in otherwise inaccessible populations, and supports the generation of evidence where traditional data sources are insufficient.
methodsA tree-based decision model was applied to generate synthetic data based on an existing set of real-world data (RWD) from the Chronic Urticaria Registry (CURE). Descriptive characteristics and association strength between relevant RWD variables and their synthetic counterparts were analyzed as indicators of replication accuracy, providing insight into how closely the synthetic data aligns with the RWD. Finally, we determined the minimum sample size required to generate high-quality synthetic data.
resultsThe algorithm produced extensive synthetic data records, closely mirroring patient demographics and disease clinical characteristics. Smaller subgroups of the data were equally replicated and followed the same distribution as RWD. Known associations and correlations between disease-specific factors (disease control) and risk factors (age) yielded similar results, with no significant difference (p > 0.05). The lowest threshold at which synthetic data could be generated while maintaining high accuracy in RWD was identified to be 25%, enabling a fourfold increase in the synthetic population.
conclusionSynthetic data could replicate RWD with reasonable accuracy for patients with CSU down to 25% of the original population size. This method has the potential to extend small patient subgroups in clinical and epidemiological research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.